To verify the efficacy and safety of Original Perfusor Line (Art.No.8723017) in infusion therapy in Patients with light sensitive drug infusion. Subjects who choose to use Original Perfusor Line for their planned infusion treatment (nimodipine injection) as per the study protocol will be enrolled. The 300 subjects will be 1:1 randomized into the experimental group or the control group, using Original Perfusor Line (Art.No. 8723017) connected with an injection pump for infusion treatment with nimodipine injection or Original Perfusor Line (Art.No.8723010) connected with an injection pump for infusion treatment with nimodipine injection, respectively.Use of both the test product and the control product will be in strict accordance with their package insert. The primary endpoint is the percentage of products which successful infuse fluids or medications into patient's circulatory system without leakage of fluids or medications, visible catheter embolism, air embolism and micro embolism in the infusion system and the secondary endpoint is the quality assessment for the clinical application of the products,such as the percentage of products which are qualified for infusion administration including link and removal, transparence, and tenacity.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Enrollment
300
Patients with nimodipine pump infusion with pump infusion line and other infusion equipments
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Sanbo Brain Hospital, Captial Medical University
Beijing, Beijing Municipality, China
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Infusion success rate
The percentage of products which successful infuse fluids or medications into patient's circulatory system without leakage of fluids or medications
Time frame: 2 hours after infusion therapy completion
Product pass rate
percentage of the quantity of products that pass the evaluation in the sum of products that pass the evaluation and products that fail the evaluation.
Time frame: 2 hours after infusion therapy completion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.